Biosynthetic hematopoietic agent that principally affects the proliferation and differentiation of neutrophils within the bone marrow; a covalent conjugate of filgrastim (a human granulocyte colony-stimulating factor [G-CSF]) and monomethoxypolyethylene glycol (PEG). Uses for Pegfilgrastim Chemotherapy-induced Neutropenia Reduction of the risk of infectious complications (as manifested by febrile neutropenia) in patients with nonmyeloid malignancies receiving myelosuppressive antineoplastic therapy that is associated with a clinically important risk of severe neutropenia with fever. Efficacy comparable to that of filgrastim, but requires less frequent administration. Efficacy not established in patients receiving antineoplastic therapy associated with delayed myelosuppression (e.g., nitrosourea derivatives, mitomycin), in those receiving myelosuppressive doses of antimetabolites (e.g., cytarabine, fluorouracil), or in those receiving radiation therapy. (See Specific Drugs under Interactions.) Pegfilgrastim Dosage and Administration Administration Sub-Q Administration Administer by sub-Q injection.

Apexus Drug Monograph – Tbo-filgrastim 20. Filgrastim and an unspecified reference filgrastim product for peripheral blood stem cell mobilization and allogenic stem cell transplantation in 22 healthy donors. Study medication was administered at a dose of 10 mcg/kg twice daily for 9 doses. 2015–2020 Biologics Monographs 2 – Proteins (BIO2) Expert Committee Wednesday – Thursday, September 27-28, 2017. USP – U.S., Rockville. Agenda _____ Goals and Anticipated Outcomes. To update EC’s 2015-2020 work plan 2. To update new proposals, revision proposals and EP activities 3.

Do not shake the injection. Dosage Dosage modification based on body weight not required. Adults Chemotherapy-induced Neutropenia Sub-Q 6 mg administered once per chemotherapy cycle. Do not administer during the 14 days before or 24 hours after administration of cytotoxic chemotherapy. (See Specific Drugs under Interactions.) Cautions for Pegfilgrastim Contraindications • Known hypersensitivity to pegfilgrastim, filgrastim, any ingredient in the formulation, or proteins derived from Escherichia coli.

Warnings/Precautions Warnings Splenic Rupture Splenic rupture (including fatalities) reported rarely following administration of filgrastim for peripheral blood progenitor cell (PBPC) mobilization in both healthy donors and patients with cancer. Do not use pegfilgrastim for this purpose. Evaluate patients experiencing left upper abdominal or shoulder tip pain for the presence of splenomegaly or splenic rupture. Respiratory Effects Adult respiratory distress syndrome (ARDS) reported in neutropenic patients with sepsis receiving filgrastim. Evaluate neutropenic patients receiving pegfilgrastim for the presence of ARDS if fever, lung infiltrates, or respiratory distress develops.

If ARDS occurs, provide appropriate treatment for ARDS and discontinue or withhold pegfilgrastim until ARDS has resolved. Adi 1882 hd audio codec driver. Testi pa belaruskaj ltaraturi 11 klas. Sickle Cell Disease Severe sickle cell crisis reported in patients with sickle cell disease (specifically, homozygous sickle cell anemia, sickle cell-hemoglobin C disease, and sickle cell-β+-thalassemia disease) receiving filgrastim for PBPC mobilization or following chemotherapy. Use pegfilgrastim with caution in patients with sickle cell disease and only after carefully considering potential risks and benefits. Patients with sickle cell disease should be well hydrated and monitored for sickle cell crisis during therapy.